Our Team

Aruni S. Arachchige Don, PhD
Senior Consultant

Aruni S. Arachchige Don, PhD

Senior Consultant

Aruni is a Senior Consultant and Project Lead for Payer/Market Access. Aruni has contributed to projects that span the therapeutic landscape and leads the respiratory disease franchise at DH. Aruni received a PhD in Pharmacology. Prior to DH, Aruni completed a postdoctoral fellowship in collaboration with the W.M. Keck Center for Collaborative Neuroscience.

Click Here for Full Bio

[CLOSE]

Aruni S. Arachchige Don, PhD

Senior Consultant

Aruni is a Senior Consultant and Project Lead for Payer/Market Access at Defined Health. Aruni’s client work encompasses opportunity assessments, therapeutic area growth strategy, asset search & evaluation, forecasting and value-based pricing modeling. Since joining Defined Health in 2013, Aruni has contributed to projects that span the therapeutic landscape, including oncology, CNS, autoimmune & inflammatory, dermatology, gene & cell therapies, and she currently leads the respiratory disease franchise at Defined Health.

Prior to joining Defined Health, Aruni conducted translational research on targeting mTOR signaling for treatment of CNS injuries (e.g., traumatic brain and spinal cord injuries) and cancer. During her postdoctoral tenure, Aruni also interned at the Office of Technology Transfer and Business Development, where she was involved in various aspects of business development and licensing and developed proficiency in identification and evaluation of novel technologies appropriate for commercialization.

Aruni received a PhD in Pharmacology from the University of Iowa, Carver College of Medicine. She also earned Bachelor of Science degrees in both Biology and Microbiology from the University of Wisconsin, Madison and from the University of Minnesota, Twin Cities. Aruni is an Advisory Board Member of the Mountain Lakes Biotech Academy and is a member of the Alliance for Regenerative Medicine (ARM) Market Access & Value Committee. She is a published author of multiple peer-reviewed articles.

Jeffrey M. Bockman, PhD
EVP, Head of Oncology Practice

Jeffrey M. Bockman, PhD

EVP, Head of Oncology Practice

Jeff Leads the Oncology at DH, the firm’s largest practice area. He earned his PhD from Berkeley in Molecular Virology, working on prions, and completed a post-doc at The George Washington School of Medicine. His first stint in industry was at a start-up biotech working on oligonucleotide therapeutics for cancer and infectious diseases.

Click Here for Full Bio

[CLOSE]

Jeffrey M. Bockman, PhD

EVP, Head of Oncology Practice

Jeff leads the Oncology and Virology Practices at Defined Health. The cancer practice is DH’s largest therapeutic area.

Before joining Defined Health, Jeff was a Senior Research Scientist and Research Project Leader in the commercial development of oligonucleotide therapeutics for viral diseases and cancer at Innovir Laboratories; and an Assistant Research Professor at The George Washington University School of Medicine.

He received a BA from University of California at San Diego, and a PhD in Medical Microbiology from the University of California at Berkeley, working with Drs. David Kingsbury and Stanley Prusiner on prions. He also earned an MA in English/Creative Writing from New York University.

Jeff is a member of the Licensing Executives Society (LES), the American Association for Cancer Research (AACR), the American Society of Clinical Oncology (ASCO), the American Society of Hematology (ASH), and the American Society of Gene and Cell Therapy (ASGCT), The Society for Immunotherapy of Cancer (SITC), and the New York Academy of Sciences (NYAS).

Janet Czachura
Principal

Janet Czachura

Principal

Janet leads the Search and Evaluation Practice at DH, and has over 30 years of scientific and pharmaceutical experience. Her background includes academia and global large pharma, with experience in partnering & research acquisition, competitive strategic analysis, regulatory, and knowledge management.

Click Here for Full Bio

[CLOSE]

Janet Czachura

Principal

Janet joined Defined Health in 2008, bringing over 17 years of large pharma experience to the company. Since joining, Janet has assumed a leadership role for Defined Health’s product search and evaluation business, working collaboratively with the therapeutic area heads. She has led development of a proprietary internal database management software tool to facilitate compound and company assessments.

Janet previously spent 6 years at Hoffmann-La Roche as a Manager of Market Intelligence in the Pharma Partnering division, focusing on information management and analysis for Acquisitions & Strategic Alliances. There she was involved in and led a number of competitive landscape, company profile and pipeline analysis projects. Prior to Roche, Janet spent 11 years at Eli Lilly & Company, first as an electrophysiologist in the Neuroscience division, and subsequently assuming senior associate positions with increasing responsibility in Research Acquisition and Corporate Strategic Analysis supporting in-licensing activities and senior management strategic decisions. Janet spent 6 years in academia working on electrophysiological and behavioral studies in the area of drug withdrawal.

Janet has Bachelor degrees in Biological Sciences and Psychology from Southern Illinois University. She is a member of the Licensing Executives Society, Regulatory Affairs Professionals Society, and Society of Competitive Intelligence Professionals.

Ginger S. Johnson, PhD
Chief Executive Officer

Ginger S. Johnson, PhD

Chief Executive Officer

Ginger is CEO and CNS Practice Co-Lead. Her background ranges from basic scientific research to private equity investment. Ginger was a Director at Chase Capital Partners private equity firm, Associate Director of the Center for Biotechnology at Northwestern University and conducted basic and applied research at the National Institute of Mental Health.

Click Here for Full Bio

[CLOSE]

Ginger S. Johnson, PhD

Chief Executive Officer

Ginger participates in and manages core assessment and strategic consulting projects, with special emphasis on CNS-associated therapeutic categories. Her background spans both the science and business of healthcare, ranging from basic scientific research to private equity investment and corporate development.

Ginger was Vice President, Corporate Development at Skila, where she was responsible for the identification and execution of strategic partnerships and, with an executive team, for the definition of corporate strategy. As the Director of Life Science Research at Chase Capital Partners (now JP Morgan Partners), a $25 billion global private equity firm, Ginger’s research and investment activities focused on high growth opportunities in new and emerging areas within the pharmaceutical, biotechnology, medical device, and eHealth industries.

Ginger was Associate Director of the Center for Biotechnology at Northwestern University, where she helped to develop an innovative graduate program that combines the science and business of biotechnology. She spent eight years in basic and applied scientific research, primarily in the field of Alzheimer’s disease, at the NIH and at Molecular Geriatrics, a start-up biotechnology company. She joined Defined Health in 2001.

Ginger has published 14 peer-reviewed articles, presented over 20 abstracts, and has been issued three patents. She earned her Bachelor of Science degree in Molecular Biology from University of Tennessee, a Doctorate in Genetics from George Washington University in Washington, DC, and has completed graduate studies at the Kellogg Graduate School of Management at Northwestern University.

James T. Lee, PhD
Associate Principal

James T. Lee, PhD

Associate Principal

James has 10 years of experience in the oncology space spread across academic research, biotech, and business and clinical development strategy consulting. He is currently helping to lead the oncology practice alongside other senior oncology team members.

Click Here for Full Bio

[CLOSE]

James T. Lee, PhD

Associate Principal

James has extensive research, commercial, and strategic perspective on the pharmaceutical and biotech industries. He has a strong expertise in oncology, particularly immuno-oncology, where he has led many client engagements ranging from commercial opportunity assessments to portfolio/platform management. He has helped clients navigate many potential BD&L issues, ranging from in- and out-licensing opportunities and evaluating precommercial biotech clinical development paths.

Before joining Defined Health, James was a Scientist and Oncology Personalized Medicine Project Leader and was involved in numerous preclinical neuroscience and translational oncology projects at Psychogenics. During that time, he managed a diverse collaborative effort to discover and validate drug discovery and preclinical tools for both clients and patients. Previously he completed his postdoctoral fellowship at Columbia University in Oncology in the laboratory of Dr. Wei Gu working with tumor suppressors p53 and PTEN (in collaboration with Dr. Ramon Parsons).

He received a BA from Rutgers University, a PhD in Neuroscience from Emory University, where he studied the molecular mechanisms

Ginny E. Llobell
Senior VP, Business Development and Marketing

Ginny E. Llobell

Senior VP, Business Development and Marketing

Ginny has held senior level positions in Business Development, Corporate Development, Strategy, Marketing, and Operations over the course of her 30+ year career in the Life Sciences, at Itohchu, The Center for Biotechnology at Stony Brook University and Defined Health. She earned a BS with distinction from Cornell University.

Click Here for Full Bio

[CLOSE]

Ginny E. Llobell

Senior VP, Business Development and Marketing

Ginny currently heads up business development, corporate development, operations and administration at Defined Health, and oversees the production of Defined Health’s two conferences, Therapeutic Insight by Defined Health at BioEurope Spring, and Cancer Progress. For many years prior in her career at Defined Health, Ginny managed client studies in various therapeutic areas, including in-depth opportunity assessments, asset searches, and partnering initiatives for both US and Japanese clients.

Prior to joining Defined Health, Ginny was Manager of New Business Development for a US division of Itochu, where she was responsible for identifying and negotiating opportunities for distribution of US products and technologies in Japan, including computer-based protein engineering, molecular modeling, and information management systems. Previously, she was Acting Director of the New York State Center for Advanced Technology in Medical Biotechnology, where she developed and implemented a variety of programs to help to foster the growth of a biotech industry in New York State.

Ginny received a BS with distinction from Cornell University. She is a member of New York Pharma Forum and Licensing Executives

David J. Lomb, PhD
Associate Principal

David J. Lomb, PhD

Associate Principal

David co-leads the autoimmune and inflammatory disease, and leads the fibrosis and ophthalmology practices at DH. He earned a PhD in Pharmacology from University of Rochester where his thesis focused on neuronal programmed cell death, and completed a postdoctoral fellowship in the Paul F. Glenn Laboratories for Biological Mechanisms of Aging at Harvard Medical School.

Click Here for Full Bio

[CLOSE]

David J. Lomb, PhD

Associate Principal

As an Associate Principal with Defined Health, David participates in and leads opportunity assessments as well as indication prioritization/sequencing, search, and strategy projects. David regularly contributes to projects in the oncology, dermatology, CNS, and autoimmune and inflammatory disease spaces. In addition, David leads most projects involving the fibrosis therapeutic area at Defined Health.

Prior to joining Defined Health in 2010, David was a postdoctoral fellow in the Paul F. Glenn Laboratories for the Biological Mechanisms of Aging at Harvard Medical School. As a scientist at Harvard, David studied a family of enzymes known as sirtuins which have been implicated in the regulation of aging and age-related diseases. Also while at Harvard, David was a fellow in the Early Technology Assessment Program sponsored by the Office of Technology Development. In this position, David was responsible for performing initial commercial assessments of discoveries made by Harvard faculty members.

David earned a PhD in Pharmacology from the University of Rochester, in Rochester, New York, where his thesis work focused on the molecular mechanisms of neuronal programmed cell death. David has also earned Bachelor of Science degrees in both Biochemical Pharmacology and Psychology from the University at Buffalo, in Buffalo, New York. David has published in peer reviewed scientific journals and has presented his work at national scientific meetings.

Danielle M. Marra, MS, MBA
Associate Principal

Danielle M. Marra, MS, MBA

Associate Principal

Danielle manages projects focused on opportunity assessments and therapeutic area growth strategy. She co-leads the autoimmune and inflammatory disease practice and leads the antibiotics therapeutic area. Danielle earned a MBA and Master’s degree in Molecular Biology from Rutgers University. Prior to joining DH, Danielle spent time in research at a biotech company.

Click Here for Full Bio

[CLOSE]

Danielle M. Marra, MS, MBA

Associate Principal

As an Associate Principal with Defined Health, Danielle leads projects focused on opportunity assessments, therapeutic area growth strategy, identification and evaluation of partnering opportunities, and asset valuation. She heads the antibiotic practice and co-leads the autoimmune and inflammatory practice at DH; however, her experience spans the therapeutic landscape.

Prior to joining Defined Health in 2011, Danielle was a Scientist in the Bioanalytical Development group at an emerging biotech company in New Jersey where she was responsible for the design, development, and validation of a number of immuno- and cell-based assays for use in preclinical and early phase clinical studies for metabolic and autoimmune bone diseases. Danielle was also involved in performing competitive intelligence for the Business Development team to identify potential partners for licensing, as well as competitors in the peptide therapeutic space.

Danielle received a Masters Degree in Cell and Developmental Biology and an MBA with concentrations in Pharmaceutical Management and Marketing from Rutgers University. Her Masters research focused on the NAD-dependent deacetylase, sirtuin-1, and its activity in colon, breast, and pancreatic cancer. She holds a B.S. in Biology from The College of New Jersey.

Brent W. Osborne, PhD
Consultant

Brent W. Osborne, PhD

Consultant

Brent has over 8 years of life sciences experience with a recent focus on consulting within the cardiometabolic and rare disease therapeutic areas. Brent’s Ph.D. (University of Vermont) and postdoctoral fellowship (Columbia University) focused on the identification of novel drug targets for hypertension and other cardiovascular disorders.

Click Here for Full Bio

[CLOSE]

Brent W. Osborne, PhD

Consultant

As a Consultant with Defined Health, Brent participates in opportunity assessments, indication prioritization/sequencing, search, and strategy projects. Brent regularly contributes to projects in the cardiovascular, CNS, ophthalmology, dermatology, and AIID spaces.

Before joining Defined Health, Brent was a postdoctoral fellow in the Wu Center for Molecular Cardiology at Columbia University. As a postdoc at Columbia, Brent studied the molecular mechanisms of smooth muscle function, which led to the development of two novel mouse models of hypertension. In parallel to his time at Columbia, Brent worked as an analyst for The Solution Lab (TSL), a non-profit life sciences consulting firm in NYC. During his tenure with TSL, Brent advised clients in both pharma and biotech firms develop business strategies through competitive intelligence and quantitative analyses of niche markets.

Brent earned a PhD in Cell and Molecular Biology from the University of Vermont, in Burlington, VT, where his thesis focused on structure-function relationships of novel modulators of protein kinase activity. Brent also earned a BSc from UVM in Biological Sciences where he studied the mechanisms of microbial pathogenesis. Brent has published in peer-reviewed journals, presented his work at national and international scientific meetings and is co-inventor on a patent originating from his graduate studies.

Michael C. Rice, MS, MBA
Principal

Michael C. Rice, MS, MBA

Principal

Mike is the head of DH’s Advanced Therapies and Rare Diseases practices. He has
20 years’ experience in biotech ventures defining strategic development and early commercial strategy for academic and biotech inventions pertaining to nucleic acids, gene therapy and cellular platforms applied across monogenetic diseases and oncology. Mike holds an MBA, and is a member of ASGCT, ARM, SITC, ASCO, ASH, LES, and AHA.

Click Here for Full Bio

[CLOSE]

Michael C. Rice, MS, MBA

Principal

Mike leads Defined Health’s Gene and Cell Therapeutics and Rare Diseases practices. He also co-heads the oncology practice focusing on hematologic malignancies and genetically defined cancers. Prior to Defined Health, Mike gained over a decade of experience creating new biotech ventures from academic inventions pertaining to nucleic acids and cellular platforms applied across monogenetic diseases and oncology. Industry positions involved translational research, strategic planning, technology transfer, finance and business development.

Mike holds an MBA, with a concentration in Biotechnology from the Alfred Lerner School of Business and Economics, at the University of Delaware, an MS in Molecular Pharmacology from Thomas Jefferson University and a Bachelor of Science degree in Biology from the University of Delaware. Mike studied the molecular basis of cancer at the Kimmel Cancer Institute and is recognized for his extensive intellectual property and publication portfolio pertaining to cancer genetics, recombinational DNA repair, gene therapy, diagnostics, and agricultural trait improvement.

Mike is a member of the American Society of Gene and Cell Therapy (ASGCT), the Alliance for Regenerative Medicine (ARM), the Society for Immunotherapy of Cancer (SITC), the American Society of Clinical Oncology (ASCO), the American Society of Hematology (ASH), the Licensing Executives Society (LES), and the American Heart Association (AHA).

Ed Saltzman
Executive Chairman

Ed Saltzman

Executive Chairman

Ed leverages his 30+ years of experience working at the intersection of science and strategy to deliver value driving advice to early stage biotech companies.

Click Here for Full Bio

[CLOSE]

Ed Saltzman

Executive Chairman

Ed Saltzman is President and Founder of Defined Health, a leading strategic business development advisory firm serving senior executives in pharma, biotech and investment sectors. Leveraging 25+ years of experience consulting for biopharma companies, he provides guidance to Defined Health’s senior project leadership who work with clients across multiple therapeutic areas. Ed is an in demand speaker on industry issues and has been recognized widely as an early “spotter” of key trends that go on to have significant impact within the life sciences industry, especially as these pertain to the licensing and business development field. He notably coined the term “Proof of Relevance,” to describe indisputable demonstration of clinical and economic value in drug development. He is a recent recipient of the LES Frank Barnes Mentoring Award for his contributions to education in the life sciences sector. Ed is an advisor to the Israel Biotech Fund, and a member of the Licensing Executives Society (LES) and the New York Pharma Forum. He is a graduate of New York University.

Joel S. Sandler, PhD
Associate Principal

Joel S. Sandler, PhD

Associate Principal

Joel applies analytic focus and relentless curiosity honed over years as a business development executive and PhD-trained scientist to deliver client-centric solutions towards the effective positioning and partnering of therapeutic candidates being developed within competitive oncology and CNS landscapes.

Click Here for Full Bio

[CLOSE]

Joel S. Sandler, PhD

Associate Principal

As an Associate Principal with Defined Health, Joel provides insight to various life sciences industry clientele (biotechnology/pharmaceutical) on fundamental issues in drug development and partnering based on a comprehensive analysis of the key scientific, clinical, regulatory, and commercial questions relevant to the client’s particular situation. In previous industry roles, Joel was instrumental in the scouting and evaluation of licensing and partnering opportunities for various oncology assets. Prior to his BD&L activities, Joel spent ten years focused on the discovery and characterization of bioactive compounds for cancer and infectious disease research at several leading academic institutions. His work has resulted in numerous grants, fellowships, patent filings, and peer-reviewed publications. He received his BA with honors from Cornell University, a PhD in Organic Chemistry from UCSD, and was a NIH Postdoctoral Fellow at The Rockefeller University.